enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference

IRVINE, CA / ACCESS Newswire / August 27, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company") today announced that Robert Berman, Chief Executive Officer of enVVeno Medical, participated in the Virtual Investor "Why Now" on-demand conference. For the event, Mr. Berman highlighted the Company's investment opportunity, including the significant unmet need for effective treatment options for patients with severe Deep Venous Insufficiency (DVI) and the substantial market opportunity for Company's non-surgical replacement venous valve called enVVe. He also discussed the Company's recent achievement of the FDA IDE approval for a U.S. pivotal study evaluating enVVe, an important regulatory catalyst for the Company. The TAVVE pivotal trial is expected to commence in the fourth quarter of 2026 and ultimately enroll approximately 230 patients across up to 40 U.S. clinical sites. The trial represents an important next step towards potential regulatory approval of the enVVe System, a first-in-class bioprosthetic venous valve designed to address the underlying cause of severe DVI, and a significant potential value-driving catalyst for enVVeno Medical.